UBS Group AG trimmed its position in shares of STERIS plc (NYSE:STE – Get Rating) by 17.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 129,414 shares of the medical equipment provider’s stock after selling 26,560 shares during the quarter. UBS Group AG owned 0.13% of STERIS worth $26,679,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently bought and sold shares of STE. Tcwp LLC purchased a new position in STERIS during the 1st quarter worth $25,000. 1832 Asset Management L.P. bought a new stake in shares of STERIS during the 1st quarter worth $25,000. Urban Wealth Management LLC bought a new stake in shares of STERIS during the 2nd quarter worth $33,000. J.W. Cole Advisors Inc. bought a new stake in shares of STERIS during the 1st quarter worth $37,000. Finally, Standard Family Office LLC bought a new stake in shares of STERIS during the 1st quarter worth $43,000. 92.04% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on STE shares. StockNews.com started coverage on STERIS in a research note on Wednesday, October 12th. They set a “buy” rating on the stock. Needham & Company LLC cut STERIS from a “buy” rating to a “hold” rating in a research note on Friday, September 23rd. KeyCorp lowered their target price on STERIS from $240.00 to $210.00 and set an “overweight” rating on the stock in a research note on Friday, November 11th. TheStreet upgraded STERIS from a “c+” rating to a “b” rating in a research note on Tuesday, August 2nd. Finally, JMP Securities lowered their price objective on STERIS from $270.00 to $250.00 in a research note on Thursday, August 4th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $242.40.
STERIS Price Performance
STERIS (NYSE:STE – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The medical equipment provider reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.01. STERIS had a positive return on equity of 12.75% and a negative net margin of 0.17%. The firm had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.22 billion. During the same period in the prior year, the business posted $1.99 earnings per share. The company’s revenue was up .3% on a year-over-year basis. On average, equities research analysts forecast that STERIS plc will post 8.45 earnings per share for the current fiscal year.
STERIS Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, December 16th. Stockholders of record on Tuesday, November 22nd will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 1.04%. The ex-dividend date of this dividend is Monday, November 21st. STERIS’s dividend payout ratio is presently -1,708.94%.
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
- Get a free copy of the StockNews.com research report on STERIS (STE)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.